OPTHEA
Opthea Limited (formerly Circadian Technologies) is a public Australian biotechnology company developing novel biologic therapies for the treatment of eye diseases. Opthea's lead compound, OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD).
OPTHEA
Industry:
Biopharma Biotechnology Health Care Life Science Medical Device Pharmaceutical
Founded:
1984-01-01
Address:
South Yarra, Victoria, Australia
Country:
Australia
Website Url:
http://www.opthea.com
Total Employee:
11+
Status:
Active
Contact:
+61398260399
Email Addresses:
[email protected]
Total Funding:
237.95 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome Global Site Tag
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Biotron
Biotron Limited is an Australian biotechnology company based in Sydney, NSW.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
ImmunOs Therapeutics
ImmunOs Therapeutics is a clinical-stage biotechnology company.
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Origin Agritech
Origin Agritech is a leading agricultural biotechnology company.
Panacea Biotec
Panacea Biotec is an Innovation driven Biotechnology company.
Current Employees Featured
Founder
Stock Details
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-03 | Opthea Appoints Chief Commercial Officer to Lead Commercialization of OPT-302 for Wet AMD |
Official Site Inspections
http://www.opthea.com Semrush global rank: 6.83 M Semrush visits lastest month: 758
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Opthea"
Opthea - Revolutionizing Treatment of Wet AMD
Opthea - We Aim to Improve the Treatment of Wet AMD Through Bold Scientific Innovation We envision a future where the impact of wet AMD is minimized and quality of vision and life is maximized. We have a team of passionate โฆSee details»
Opthea - Crunchbase Company Profile & Funding
Opthea Limited (formerly Circadian Technologies) is a public Australian biotechnology company developing novel biologic therapies for the treatment of eye diseases.See details»
Opthea Announces Executive Leadership Changes and Senior Hires
Sep 5, 2024 Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical Company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive โฆSee details»
Management Team - Opthea
Oct 8, 2024 Bonifazio joins Opthea from Astellas (former IVERIC BIO) where he served as Vice President,... John Han. by Shari Basch | Oct 8, 2024 | Company, Management Team. Dr. โฆSee details»
Opthea Announces Executive Leadership Changes and Senior Hires
Sep 5, 2024 The following organizational changes further deepen the Companyโs expertise in retina, expand its clinical capabilities, while advancing Optheaโs commercial readiness, in โฆSee details»
Opthea Limited - AnnualReports.com
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia.See details»
Opthea Limited (ASX: OPT) Company Profile & Overview - Stock โฆ
Nov 4, 2024 Company profile for Opthea Limited (ASX: OPT) with a description, list of executives, contact details and other key facts.See details»
Opthea Company Profile - Office Locations, Competitors, Revenue โฆ
Sep 12, 2024 Opthea (formerly Circadian Technologies) is a biopharmaceutical company developing a therapy for the treatment of retinal diseases. Its technology blocks two members โฆSee details»
Opthea to Have Significant Presence at the 24แตสฐ EURETINA โฆ
Sep 10, 2024 Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive โฆSee details»
Opthea Reports Half-Year Financial Results and Business Updates
Dec 31, 2023 Opthea (ASX:OPT; NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and โฆSee details»
Opthea Appoints Kathy Connell to Board of Directors - Yahoo โฆ
Nov 15, 2024 Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 โฆSee details»
Board Of Directors - Opthea
Nov 15, 2024 Skip to Main Content Get Opthea Updates. Company. Company Overview; Management Team; Board of Directors; Medical Advisory Board; COAST and ShORe Steering โฆSee details»
Opthea Appoints Kathy Connell to Board of Directors
Nov 15, 2024 Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive โฆSee details»
OPT News, Analysis, Announcements & Results | Opthea Limited
3 days ago The Carlyle Group and its newly acquired life sciences arm Abingworth are chasing a four-bagger at Australian eye therapies developer Opthea. Itโs a big day for ASX-listed โฆSee details»
Opthea Appoints Kathy Connell to Board of Directors
Nov 18, 2024 Optheaโs lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) โฆSee details»
Opthea Appoints Kathy Connell to Board of Directors
Nov 15, 2024 Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive โฆSee details»
Opthea To Present at Clinical Trials at the Summit Meeting
Jun 3, 2024 Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive โฆSee details»
Anthony Bonifazio - Opthea
Oct 8, 2024 During his tenure at Novartis, Mr. Bonifazio built a 180-person organization for the launch of the first physician-administered, buy and bill product in cardiology, shaping the โฆSee details»
Optheaโs Wet AMD Program to be Featured at FLORetina 2024
Nov 26, 2024 MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, โOptheaโ, the โCompanyโ), a clinical โฆSee details»
Opthea to Participate in Citi 2024 Global Healthcare Conference
Nov 25, 2024 Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive โฆSee details»